Stereotactic Hypofractionated body radiosurgery for Oligometastatic Renal cell Tumours upfront, with Systemic Targeted agents On Progressio
- Conditions
- Oligometastatic Renal Cell CancerCancer - KidneyRenal and Urogenital - Other renal and urogenital disorders
- Registration Number
- ACTRN12615000330549
- Lead Sponsor
- Peter MacCallum Cancer Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Stopped early
- Sex
- All
- Target Recruitment
- 30
Aged 18 years or older
- Histological or cytologically confirmed renal cell carcinoma
- Bone Scan or CT Scan evidence of 1 to 3 extracranial metastases in patients with no prior systemic targeted therapy
-Bone Scan or CT Scan evidence of 4 to 6 extracranial metastases in patients currently on systemic targeted therapy AND no more than 1 to 3 progressing metastases
- An ECOG performance status score of 2 or less
- Life expectancy greater than 9 months
- Available for follow up
- Previous high dose radiotherapy (BED > 20Gy) to the area to be treated
- Intracranial metastases not controlled by previous surgery or stereotactic radiotherapy
- Chemotherapy within +/- 3 weeks of SABR
- Systemic targeted agents within +/- 7 days of SABR
- Evidence of Spinal Cord Compression
- Spinal Instability Neoplastic Score >= 7 unless case has been reviewed by a neurosurgical service and considered stable
- Long bone Mirels score >= 7 unless reviewed by an orthopaedic service and considered stable
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ocal progression free survival (LPFS) at 1 year of patients receiving SABR.[2 year after completion of accrual. LPFS will be assessed by a combination of RECIST Criteria definitions taken using CT scans in participant's medical records. CT scans will be performed at baseline and then every 3 months during follow-up for each participant for up to 1 years.]
- Secondary Outcome Measures
Name Time Method